1065: Pharmacist Impact on Transitions of Care From the Intensive Care Unit: Readmission Rates

2020 ◽  
Vol 49 (1) ◽  
pp. 533-533
Author(s):  
Abby Chiappelli ◽  
Sandra Kane-Gill ◽  
Pamela Smithburger
2020 ◽  
pp. 089719002091152
Author(s):  
Mikhaila Rice ◽  
Alyssa Lear ◽  
Sandra Kane-Gill ◽  
Amy L. Seybert ◽  
Pamela L. Smithburger

Objective: Do pharmacy personnel- (ie, pharmacist or pharmacy technician) driven interventions at transitions of care into or out of the intensive care unit (ICU) improve medication safety measures compared to interventions made by other health-care team members or no intervention? Data Sources: A literature search of MEDLINE and Embase limited to English language and humans was performed (from 1969 until January 2019). Bibliographies of included investigations were reviewed for additional citations. Methods: Investigations were selected if they described a pharmacy-driven intervention at any point of transfer into or out of an ICU setting. Ten investigations were included. Five described interventions relevant to the entire ICU population, and 5 described interventions targeted to specific medications or disease. Results: A variety of interventions were utilized in the 10 included investigations. A significant improvement was demonstrated with pharmacy-driven intervention in all 4 studies that evaluated the entire ICU patient population. Interventions specific to certain medication and disease improved medication safety measures but were not always statistically significant. Medication error rates are high in patients transferred into and out of the ICU, and limited data exist to address this concern. This review compares and evaluates the current literature to guide future interventions and research in this area. Conclusions: Although pharmacy-driven interventions demonstrated some benefit in various medication safety measures in the majority of studies, additional randomized and prospective trials with patient-centered outcomes that assess morbidity and mortality are needed.


2020 ◽  
Vol 32 (2) ◽  
Author(s):  
Ahmed Naji Balshi ◽  
Basim Mohammed Huwait ◽  
Alfateh Sayed Nasr Noor ◽  
Abdulrahman Mishaal Alharthy ◽  
Ahmed Fouad Madi ◽  
...  

CHEST Journal ◽  
2012 ◽  
Vol 142 (4) ◽  
pp. 278A ◽  
Author(s):  
Uchenna Ofoma ◽  
Rahul Kashyap ◽  
Craig Daniels ◽  
Ognjen Gajic ◽  
Brian Pickering ◽  
...  

2020 ◽  
Vol 49 (1) ◽  
pp. 557-557
Author(s):  
Kelsey Beatrous ◽  
Katherine Artman ◽  
Stephanie Tesseneer

2020 ◽  
Vol 51 (4) ◽  
pp. 318-326 ◽  
Author(s):  
Andrew S. Allegretti ◽  
Paul Endres ◽  
Tyler Parris ◽  
Sophia Zhao ◽  
Megan May ◽  
...  

Background: Continuous renal replacement therapy (CRRT) is commonly employed in the intensive care unit (ICU), though there are no guidelines around the transition between CRRT and intermittent hemodialysis (iHD). Accelerated venovenous hemofiltration (AVVH) is a modality utilizing higher hemofiltration rates (4–5 L/h) with shorter session durations (8–10 h) to “accelerate” the clearance and volume removal that normally is spread out over a 24-h period in CRRT. We examined AVVH as a transition therapy between CRRT and iHD, with the aim of decreasing time on CRRT and providing a more graduated transition for hemodynamically unstable patients requiring RRT. Methods: Retrospective cohort study describing the clinical outcomes and quality initiative experience of the integration of AVVH into the CRRT program at an academic tertiary care center. Outcomes of interest included mortality, ICU length of stay and readmission rates, and technical characteristics of treatments. Results: In total, 97 patients received a total of 298 AVVH treatments (3.1 ± 3.3 treatments per patient). Totally, 271/298 (91%) treatments were completed successfully. During an average treatment time of 9.5 ± 1.6 h with 4.2 ± 0.5 L/h ­replacement fluid rate, urea reduction ratio was 23 ± 26% per 10-h treatment, and net ultrafiltration volume was 2.4 ± 1.3 L/treatment. Inpatient mortality was 32%, mean total hospital length of stay was 54 ± 47 days. Sixty-four out of 97 (66%) patients recovered renal function by discharge. Among those who transferred out of the ICU, 7/62 (11%) patients required readmission to the ICU after developing hypotension on iHD. Conclusion: AVVH can serve as a transition therapy between CRRT and iHD in the ICU and has the potential to decrease total time on CRRT, improve patient mobility, and sustain low ICU readmission rates. Future study is needed to analyze the implications on resource use and cost of this modality.


Sign in / Sign up

Export Citation Format

Share Document